Compare RYAAY & KVUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RYAAY | KVUE |
|---|---|---|
| Founded | 1985 | 2022 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Air Freight/Delivery Services | Specialty Chemicals |
| Sector | Consumer Discretionary | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.8B | 36.9B |
| IPO Year | 2003 | 2023 |
| Metric | RYAAY | KVUE |
|---|---|---|
| Price | $55.02 | $19.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $78.00 | $19.45 |
| AVG Volume (30 Days) | 1.1M | ★ 18.1M |
| Earning Date | 05-18-2026 | 05-07-2026 |
| Dividend Yield | 1.54% | ★ 4.82% |
| EPS Growth | N/A | ★ 40.74 |
| EPS | N/A | ★ 0.48 |
| Revenue | N/A | ★ $15,124,000,000.00 |
| Revenue This Year | $11.99 | $4.85 |
| Revenue Next Year | $6.32 | $2.63 |
| P/E Ratio | ★ $12.60 | $39.17 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $53.14 | $14.02 |
| 52 Week High | $74.24 | $21.78 |
| Indicator | RYAAY | KVUE |
|---|---|---|
| Relative Strength Index (RSI) | 33.36 | 47.60 |
| Support Level | $53.22 | $18.67 |
| Resistance Level | $61.54 | $19.07 |
| Average True Range (ATR) | 1.07 | 0.44 |
| MACD | -0.39 | -0.07 |
| Stochastic Oscillator | 3.99 | 27.62 |
Ryanair is Europe's largest low-cost airline, known for its extensive network and highly efficient business model. Operating over 3,600 flights daily across 240-plus destinations in 40 countries, Ryanair has built its success on offering affordable air travel while maintaining tight control over costs. The airline primarily uses Boeing 737 aircraft, including the newer 737 8-200 "Gamechanger" variant, which simplifies operations and reduces expenses. Ryanair focuses on high passenger volume, ancillary revenue, and operational efficiency, ensuring its position as a leading airline in Europe.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.